Medical Developments International

European Approvals And Distribution Partnerships Will Expand Global Reach

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

14 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

24.7%

-10.5%

24.7%

-10.5%

You can edit this narrative until May 14 8:10 PM. Then, changes will post as Updates.

Author's Valuation

AU$2.2775.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

AU$2.27

75.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

10.07%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.67%

Calculation

AU$4.30m

Earnings '28

71.22x

PE Ratio '28

AU$306.24m

Market Cap '28

AU$306.24m

Market Cap '28

112.66m

No. shares '28

AU$2.72

Share Price '28

AU$2.72 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$2.25

Fair Value '25